Published Research May 10, 2023 Innovative treatment for prostate cancer shows long-term success Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer death worldwide. Despite decades of research and multiple treatment options including chemo and hormone therapies, many patients still experience worsening disease and develop metastatic castration-resistant prostate cancer (mCRPC), which is typically fatal. Providing these patients with access to improved treatments may help them to survive longer and improve their quality of life. PHM’s research has been published in the peer-reviewed publication “Frontiers in Oncology.” In this case report, we summarize the treatment course for a 73-year-old male patient, who came to PHM for assistance in managing his mCRPC. Read More
Ask Our Experts April 27, 2023 What to Know About a “Breakthrough” Weight Loss Drugs The drugs, Wegovy® and Ozempic® have been in the news and trending on social media due to their unprecedented success in helping people lose large amounts of weight. Our experts at PHM answer some common questions about the recently FDA approved drug, Wegovy. Read More
Ask Our Experts April 27, 2023 Women’s heart health risk: 1 in 3 deaths each year Cardiovascular diseases, including heart attack and stroke, cause 1 in 3 deaths in women each year1. Some symptoms that women commonly experience during a heart attack are more subtle than the “classic” male symptoms. As a result, many women may not realize they are having a cardiovascular emergency and fail to seek treatment. Here, PHM share valuable information about heart attack and strokes in women, including new tools that are available for managing your heart health, along with symptoms, prevention, and risk management. Read More
Podcasts April 17, 2023 Sophisticated Solutions for Complex Cancer Care In the latest episode of the Springbuk podcast, Natalya Gertsik, Ph.D., Vice President, ClearCancer Solution Management, at Private Health Management, and a contributor to the 2023 Springbuk Employee Health Trends report, joins Jennifer Jones and Mike Pattengale to chat through sophisticated solutions for complex cancer care. Read More
Published Research January 26, 2023 An Inside Look at Employee Health Trends PHM is pleased to be a contributing partner to Springbuk’s 2023 Employee Health Trends report. The newly released report provides recommendations that will impact how benefits leaders plan, deliver, and evaluate employee benefits programs. Effects of COVID-19 on costs and health Surges in cancer costs Specialty drug use Telemedicine & mental health services Dr. Natalya Gertsik, PHM’s Vice President, ClearCancer Solution Management, offers key insights on earlier cancer detection, improving outcomes, and reducing cancer-related spending. Read More
Ask Our Experts January 26, 2023 FDA Approves New Alzheimer’s Treatment: What to know About Leqembi® (lecanemab) Leqembi® (lecanemab) was approved to treat Alzheimer’s disease in January, 2023 under the FDA’s Accelerated Approval process for diseases with an unmet need for treatment.1 The manufacturers, Eisai pharmaceuticals, plan to submit data for full FDA approval by the end of March 2023. Here, we answer some common questions about Leqembi and summarize what is known about its safety and effectiveness. Patients and their families should speak with their physician and weigh the potential benefits and risks before deciding whether to seek treatment with Leqembi. Read More
